Investment Thesis
Ocular Therapeutix is a pre-profitable biotech company with critically low revenue of $10.8M that is declining 18.5% YoY, combined with severe operating losses exceeding $93M annually. While the $666.7M cash position provides substantial runway (~9.4 years at current burn), the inability to generate meaningful revenue growth and the $70.7M annual free cash flow burn raise fundamental questions about business viability.
Strengths
- Fortress balance sheet with $666.7M cash and minimal leverage (D/E 0.04x)
- Exceptional liquidity position with 14.81x current ratio reducing bankruptcy risk
- 9+ year cash runway at current burn rate provides time for product commercialization
Risks
- Revenue declining 18.5% YoY from minimal $10.8M base indicates failed commercialization trajectory
- Operating losses of $93.3M against $10.8M revenue (-865.5% margin) demonstrates broken unit economics
- Annual free cash burn of $70.7M is unsustainable without significant revenue growth or cost restructuring
Key Metrics to Watch
- Revenue trend reversal - must demonstrate YoY growth within next 2-3 quarters
- Operating cash burn rate - any acceleration would threaten runway; improvement critical
- Product pipeline advancement and clinical trial outcomes for future revenue drivers
Financial Metrics
Revenue
10.8M
Net Income
-88.6M
EPS (Diluted)
$-0.40
Free Cash Flow
-70.7M
Total Assets
732.5M
Cash
666.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-865.5%
Net Margin
-821.6%
ROE
-15.2%
ROA
-12.1%
FCF Margin
-655.1%
Balance Sheet & Liquidity
Current Ratio
14.81x
Quick Ratio
14.73x
Debt/Equity
0.04x
Debt/Assets
20.6%
Interest Coverage
-105.23x
Long-term Debt
25.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:45:02.742071 |
Data as of: 2026-03-31 |
Powered by Claude AI